ALK and non-small cell lung carcinoma: Despite major improvements in treatment options for NSCLC, such as checkpoint inhibitors (anti‐PD‐1/PD‐L1) and targeted therapies (tyrosine kinase inhibitors in relation to epidermal growth factor receptor (EGFR), anaplastic lymphoma receptor tyrosine kinase (ALK) and ROS1 gene abnormalities), the 5‐year survival rate remains approximately 13% (Siegel et al., 2018).